DGY-06-116

Overview

DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC 50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC 50 of 8340 nM.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Pulmonary Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Src

Product Information

• Catalog No.: HY-136605
• CAS No.: 2556836-50-9
• Molecular Formula: C32H33ClN8O2
• Molecular Weight: 597.11
• Purity: 98.62%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (3.48 mM); Clear solution
• Availability: In-stock

Source

Original product source